Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (41-50 of 265) with videos related to

Pageof 27
Sort By:
Annals of Surgical Oncology|August 3, 2017
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical PracticeJessemae L Welsh, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology|July 14, 2021
Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal TherapyJennifer E Tonneson, Tanya L Hoskin, Diane M Durgan, et al.
Journal of the National Cancer Institute|April 5, 2014
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNAMatthew P Goetz, Hiltrud Brauch, Mark J Ratain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2025
Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer"Matthew P Goetz, Grace M Choong, Tanya L Hoskin, et al.
NPJ Breast Cancer|October 26, 2017
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database studyPrema P Peethambaram, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology|August 3, 2017
Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database StudyToan T Nguyen, Tanya L Hoskin, Courtney N Day, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|December 4, 2014
Pregnancy-associated plasma protein-A expression in human breast cancerAaron S Mansfield, Daniel W Visscher, Steven N Hart, et al.
Breast Cancer Research : BCR|March 14, 2012
Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivoAshwani Khurana, Hiedi McKean, Hyunseok Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to A.-S. Dieudonné et al and J.M. Rae et alHiltrud Brauch, Werner Schroth, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Tamoxifen use in postmenopausal breast cancer: CYP2D6 mattersHiltrud Brauch, Werner Schroth, Matthew P Goetz, et al.
Pageof 27

Showing results (41-50 of 265) with videos related to

Sort By:
Pageof 27
Annals of Surgical Oncology|August 3, 2017
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical PracticeJessemae L Welsh, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology|July 14, 2021
Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal TherapyJennifer E Tonneson, Tanya L Hoskin, Diane M Durgan, et al.
Journal of the National Cancer Institute|April 5, 2014
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNAMatthew P Goetz, Hiltrud Brauch, Mark J Ratain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2025
Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer"Matthew P Goetz, Grace M Choong, Tanya L Hoskin, et al.
NPJ Breast Cancer|October 26, 2017
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database studyPrema P Peethambaram, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology|August 3, 2017
Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database StudyToan T Nguyen, Tanya L Hoskin, Courtney N Day, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|December 4, 2014
Pregnancy-associated plasma protein-A expression in human breast cancerAaron S Mansfield, Daniel W Visscher, Steven N Hart, et al.
Breast Cancer Research : BCR|March 14, 2012
Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivoAshwani Khurana, Hiedi McKean, Hyunseok Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to A.-S. Dieudonné et al and J.M. Rae et alHiltrud Brauch, Werner Schroth, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Tamoxifen use in postmenopausal breast cancer: CYP2D6 mattersHiltrud Brauch, Werner Schroth, Matthew P Goetz, et al.
Pageof 27